JOINT FILING AGREEMENTJoint Filing Agreement • February 11th, 2016 • Schuler Jack W • Medicinal chemicals & botanical products
This Joint Filing Agreement is entered into as of February 11, 2016, by the undersigned, who hereby agree that the Statement on Amendment No. 3 to Schedule 13D in respect of the common shares of Transition Therapeutics Inc. is filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.
